$FLRE News - Flameret, Inc. Launches High CBD (Cannabidiol) Hemp Oil Available for Sale Immediately Throughout the United States

VENICE, FL, - (http://www.financialnewsmedia.com News Alert) - Flameret, Inc. (OTC Pink: FLRE) (PINKSHEETS: FLRE) announced today that it has launched Cannadol, a hemp oil rich in CBD (cannabidiol) which will be sold in 1 ounce bottles through its wholly-owned subsidiary Royal Hemp Corporation. The product is available immediately online on Royal Hemp\'s website (http://www.royalhempcorporation.com) and each bottle of Cannadol includes an organic hemp oil infused with 200mg of CBD. The product also includes about 1/10 of 1% THC (.1%), well beyond the legal threshold for THC content in the United States. The product will be marketed as a hemp oil dietary supplement rich in CBD and will be available for sale throughout the United States. The company is currently restricting sales outside of the United States. The product will be marketed through Royal Hemp Corporation, the company\'s recently announced Colorado wholly-owned subsidiary.



Cannabidiol (\"CBD\") is one of at least 60 active cannabinoids identified in both cannabis and industrial hemp. It is present in both plants although the prevalence or total composition of CBD can vary greatly from strain to strain.



Unlike THC (the other prevalent cannabinoid), Cannabidiol is non-psychoactive while having the potential to possess a variety of therapeutic properties in many medical conditions including cancer, epilepsy, anxiety, pain and many others. THC and CBD have an inverse relationship, the more CBD, the less THC and the reverse also holds true.



Scientific and clinical studies continue to underscore CBD\'s potential (although unproven through scientific studies) as a possible treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere. However, none of the statements regarding Cannadol or the potential therapeutic benefits of cannabidiol have been evaluated by the FDA.



John Meredith, Chief Executive Officer of Flameret, Inc. remarked,...